{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:37:56Z","timestamp":1784547476487,"version":"3.55.0"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["27378"],"award-info":[{"award-number":["27378"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Dysregulation of the Janus Kinase (JAK)\/Signal Transducer and Activator of Transcription (STAT) pathway is increasingly recognized as a central molecular hallmark in the pathogenesis of multiple rheumatic diseases. Suppressors of cytokine signaling (SOCS) proteins function as critical intracellular inhibitors of JAK\/STAT signaling through a classical negative feedback mechanism. In Rheumatoid Arthritis (RA), aberrant upregulation of SOCS1 and SOCS3 has been documented in peripheral blood T lymphocytes, monocytes, and synovial tissues, with expression levels correlating with disease activity and progression. Notably, diminished basal expression of SOCS1 mRNA is associated with poor therapeutic response to methotrexate or rituximab, and specific SOCS1 polymorphisms have been genetically linked to RA susceptibility. In Ankylosing Spondylitis (AS), enhanced SOCS3 expression in Peripheral Blood Mononuclear Cells (PBMCs), CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells, and monocytes show positive correlation with systemic inflammatory markers such as Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP), as well as with clinical indices of functional impairment. Conversely, SOCS1 expression is attenuated in T cells during phases of low-grade inflammation, suggesting context-dependent regulatory dynamics. In drug discovery for inflammatory diseases, recent advances have focused on the development of SOCS peptidomimetics, particularly those derived from the Kinase Inhibitory Region (KIR) of SOCS1, as novel immunomodulatory agents. These compounds have been shown to modulate hyperactive JAK\/STAT signaling in autoimmune conditions. In this perspective article, we analyze current progress in the development and preclinical evaluation of mimetics of SOCS proteins and discuss their prospective role in the treatment paradigm for rheumatic disorders. Herein, we propose that peptidomimetics of SOCSs may represent a new frontier in the precise modulation of JAK\/STAT signaling, offering a promising avenue toward personalized prevention and treatment of rheumatic pathologies.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2025.1708293","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T06:29:53Z","timestamp":1764311393000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic potential of peptidomimetics of suppressors of cytokine signaling (SOCS) proteins in rheumatic disorders"],"prefix":"10.3389","volume":"12","author":[{"given":"Alessia","family":"Cugudda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Marasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e59978","DOI":"10.7759\/cureus.59978","article-title":"FDA-approved Janus kinase-signal transducer and activator of transcription (JAK-STAT) inhibitors for managing rheumatoid arthritis: a narrative review of the literature.","volume":"16","author":"Potlabathini","year":"2024","journal-title":"Cureus."},{"key":"B2","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.1093\/rheumatology\/keab148","article-title":"Type 2 diabetes mellitus, glycaemic control, associated therapies and risk of rheumatoid arthritis: a retrospective cohort study.","volume":"60","author":"Zemedikun","year":"2021","journal-title":"Rheumatology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e863","DOI":"10.52225\/narra.v4i3.863","article-title":"Burden of rheumatic diseases among people with diabetes: a systematic review and meta-analysis.","volume":"4","author":"Mamadapur","year":"2024","journal-title":"Narra J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e003045","DOI":"10.1136\/rmdopen-2023-003045","article-title":"Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis.","volume":"9","author":"Su","year":"2023","journal-title":"RMD Open."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.autrev.2013.03.013","article-title":"Cardiovascular disease in autoimmune rheumatic diseases.","volume":"12","author":"Hollan","year":"2013","journal-title":"Autoimmun Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10792-019-01183-9","article-title":"Ocular manifestations of rheumatic diseases.","volume":"40","author":"Kemeny-Beke","year":"2020","journal-title":"Int Ophthalmol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrrheum.2013.185","article-title":"Ocular inflammatory diseases associated with rheumatoid arthritis.","volume":"10","author":"Artifoni","year":"2014","journal-title":"Nat Rev Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1449397","DOI":"10.3389\/fimmu.2024.1449397","article-title":"Unravelling the druggability and immunological roles of the SOCS-family proteins.","volume":"15","author":"Lynch","year":"2024","journal-title":"Front Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41589-024-01557-w","article-title":"The druggability of SH2 domains unmasked.","volume":"20","author":"Hantschel","year":"2024","journal-title":"Nat Chem Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/s41467-018-04013-1","article-title":"The molecular basis of JAK\/STAT inhibition by SOCS1.","volume":"9","author":"Liau","year":"2018","journal-title":"Nat Commun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nsmb.2519","article-title":"SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition.","volume":"20","author":"Kershaw","year":"2013","journal-title":"Nat Struct Mol Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"10736","DOI":"10.1038\/s41598-025-92150-1","article-title":"Global, regional, and national epidemiology of rheumatoid arthritis among people aged 20-54 years from 1990 to 2021.","volume":"15","author":"Zhang","year":"2021","journal-title":"Sci Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10067-006-0214-5","article-title":"Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis.","volume":"26","author":"Inanc","year":"2007","journal-title":"Clin Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"102036","DOI":"10.1016\/j.berh.2025.102036","article-title":"A review on the epidemiology of rheumatoid arthritis: an update and trends from current literature.","volume":"39","author":"Uke","year":"2025","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","article-title":"The pathogenesis of rheumatoid arthritis.","volume":"55","author":"Alivernini","year":"2022","journal-title":"Immunity."},{"key":"B16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.25259\/IJPC_395_20","article-title":"Need for palliative care in patient with rheumatoid arthritis: a cross-sectional observational study.","volume":"27","author":"Mahendru","year":"2021","journal-title":"Indian J Palliat Care."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/rheumatology\/kem198","article-title":"The expression of SOCS is altered in rheumatoid arthritis.","volume":"46","author":"Isom\u00e4ki","year":"2007","journal-title":"Rheumatology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1419951","DOI":"10.3389\/fimmu.2024.1419951","article-title":"SOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity.","volume":"15","author":"Bidgood","year":"2024","journal-title":"Front Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S1607-551X(10)70042-5","article-title":"Increased expression of suppressor of cytokine signaling 1 mRNA in patients with rheumatoid arthritis.","volume":"26","author":"Chan","year":"2010","journal-title":"Kaohsiung J Med Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13020-021-00510-6","article-title":"Shikonin attenuates rheumatoid arthritis by targeting SOCS1\/JAK\/STAT signaling pathway of fibroblast like synoviocytes.","volume":"16","author":"He","year":"2021","journal-title":"Chin Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1172\/JCI18113","article-title":"Can SOCS make arthritis better?","volume":"111","author":"Ivashkiv","year":"2003","journal-title":"J Clin Invest."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1172\/JCI13568","article-title":"Induction of the cytokine signal regulator SOCS3\/CIS3 as a therapeutic strategy for treating inflammatory arthritis.","volume":"108","author":"Shouda","year":"2001","journal-title":"J Clin Invest."},{"key":"B23","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1128\/MCB.00207-06","article-title":"Exchange protein activated by cyclic AMP (Epac)-mediated induction of suppressor of cytokine signaling 3 (SOCS-3) in vascular endothelial cells.","volume":"26","author":"Sands","year":"2006","journal-title":"Mol Cell Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1172\/JCI14661","article-title":"Putting the brakes on arthritis: can suppressors of cytokine signaling (SOCS) suppress rheumatoid arthritis?","volume":"108","author":"Rottapel","year":"2001","journal-title":"J Clin Invest."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s40744-024-00694-x","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis refractory to biologic DMARDs: results through week 216 from the SELECT-CHOICE study.","volume":"11","author":"Rubbert-Roth","year":"2024","journal-title":"Rheumatol Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"607725","DOI":"10.3389\/fmed.2020.607725","article-title":"JAK inhibitors and modulation of b cell immune responses in rheumatoid arthritis.","volume":"7","author":"Moura","year":"2020","journal-title":"Front Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"105842","DOI":"10.1016\/j.jbspin.2025.105842","article-title":"Defining a genetic background for bamboo spine and axial spondyloarthritis.","volume":"92","author":"\u00d6zkaya","year":"2025","journal-title":"Joint Bone Spine."},{"key":"B28","doi-asserted-by":"publisher","first-page":"113709","DOI":"10.1016\/j.intimp.2024.113709","article-title":"Ankylosing spondylitis: from pathogenesis to therapy.","volume":"145","author":"Wei","year":"2025","journal-title":"Int Immunopharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.3390\/jcm14113677","article-title":"The genetic background of ankylosing spondylitis reveals a distinct overlap with autoimmune diseases: a systematic review.","volume":"14","author":"Zormpa","year":"2025","journal-title":"J Clin Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12967-019-1774-x","article-title":"Protein inhibitor of activated STAT3 reduces peripheral arthritis and gut inflammation and regulates the Th17\/Treg cell imbalance via STAT3 signaling in a mouse model of spondyloarthritis.","volume":"17","author":"Min","year":"2019","journal-title":"J Transl Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbrc.2022.06.081","article-title":"IL-6 activates pathologic Th17 cell via STAT 3 phosphorylation in inflammatory joint of Ankylosing Spondylitis.","volume":"620","author":"Lee","year":"2022","journal-title":"Biochem Biophys Res Commun."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.3389\/fimmu.2018.02641","article-title":"Silencing SOCS3 markedly deteriorates spondyloarthritis in mice induced by minicircle DNA expressing IL23.","volume":"9","author":"Chen","year":"2018","journal-title":"Front Immunol."},{"key":"B33","first-page":"100","article-title":"Suppressors of cytokine signalling in ankylosing spondylitis and their associations with disease severity, acute-phase reactants and serum cytokines.","volume":"34","author":"Chen","year":"2016","journal-title":"Clin Exp Rheumatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1136\/annrheumdis-2017-eular.3832","article-title":"FRI0420 Association of supressor of cytokine signaling-3 (SOCS-3) expression with interleukin-23 receptor (IL-23R) single nucleotide polymorphisms (SNPS) in ankylosing spondylitis (AS).","volume":"76","author":"S\u00e1nchez","year":"2017","journal-title":"Ann Rheumatic Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e30330","DOI":"10.7759\/cureus.30330","article-title":"An overview of Systemic lupus erythematosus (SLE) pathogenesis, classification, and management.","volume":"14","author":"Ameer","year":"2022","journal-title":"Cureus."},{"key":"B36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study.","volume":"82","author":"Tian","year":"2023","journal-title":"Ann Rheum Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review.","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1759720X211073001","DOI":"10.1177\/1759720X211073001","article-title":"Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.","volume":"14","author":"Dima","year":"2022","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"6354","DOI":"10.1038\/s41598-021-86017-4","article-title":"Suppressor of cytokine signaling-1 mimetic peptides attenuate lymphocyte activation in the MRL\/lpr mouse autoimmune model.","volume":"11","author":"Sharma","year":"2021","journal-title":"Sci Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"210.6","DOI":"10.4049\/jimmunol.196.Supp.210.6","article-title":"Interferon-\u03b3 signaling inhibition by a suppressor of cytokine signaling-1 (SOCS-1) mimetic peptide ameliorates lupus pathology in a spontaneous mouse model.","volume":"196","author":"Collins","year":"2016","journal-title":"J Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3389\/fimmu.2017.01292","article-title":"Defective suppressor of cytokine signaling 1 signaling contributes to the pathogenesis of systemic Lupus Erythematosus.","volume":"8","author":"Wang","year":"2017","journal-title":"Front Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3389\/fimmu.2020.01336","article-title":"Identification of a human SOCS1 polymorphism that predicts rheumatoid arthritis severity.","volume":"11","author":"Lamana","year":"2020","journal-title":"Front Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1177\/0961203309357437","article-title":"Suppressor of cytokine signaling 1 gene expression and polymorphisms in systemic lupus erythematosus.","volume":"19","author":"Chan","year":"2010","journal-title":"Lupus."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1016\/S2665-9913(24)00348-5","article-title":"Clinical manifestations, disease penetrance, and treatment in individuals with SOCS1 insufficiency: a registry-based and population-based study.","volume":"7","author":"Hadjadj","year":"2025","journal-title":"Lancet Rheumatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet."},{"key":"B46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.31138\/mjr.231123.jia","article-title":"JAK inhibition as a potential treatment target in systemic Lupus Erythematosus.","volume":"35","author":"Moysidou","year":"2024","journal-title":"Mediterr J Rheumatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e000426","DOI":"10.1136\/lupus-2020-000426","article-title":"Suppressor of cytokine signalling 3 (SOCS3) expressed in podocytes attenuates glomerulonephritis and suppresses autoantibody production in an imiquimod-induced lupus model.","volume":"8","author":"Fukuta","year":"2021","journal-title":"Lupus Sci Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1604271","DOI":"10.3389\/fimmu.2025.1604271","article-title":"Research progress of SOCS in autoimmune diseases: mechanisms and therapeutic implications.","volume":"16","author":"Cui","year":"2025","journal-title":"Front Immunol."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.05.020","article-title":"New insight into the role of SOCS family in immune regulation and autoimmune pathogenesis.","author":"Liu","year":"2025","journal-title":"J Adv Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.3390\/ijms19092714","article-title":"Peptides as therapeutic agents for inflammatory-related diseases.","volume":"19","author":"La Manna","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/OARRR.S436637","article-title":"JAK-inhibitors - A story of success and adverse events.","volume":"16","author":"Wlassits","year":"2024","journal-title":"Open Access Rheumatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis.","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1314077","DOI":"10.3389\/fddsv.2023.1314077","article-title":"Introduction to small molecule drug discovery and preclinical development.","volume":"3","author":"Southey","year":"2023","journal-title":"Front Drug Discov."},{"key":"B55","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct Target Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.3390\/ijms26115131","article-title":"Therapeutic peptides: recent advances in discovery. synthesis, and clinical translation.","volume":"26","author":"Zheng","year":"2025","journal-title":"Int J Mol Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1208\/s12248-014-9687-3","article-title":"Strategic approaches to optimizing peptide ADME properties.","volume":"17","author":"Di","year":"2015","journal-title":"AAPS J."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1540192","DOI":"10.3389\/fimmu.2025.1540192","article-title":"Applications of cell penetrating peptide-based drug delivery system in immunotherapy.","volume":"16","author":"Du","year":"2025","journal-title":"Front Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/pharmaceutics16020240","article-title":"Peptide-Mediated Nanocarriers for Targeted Drug Delivery: developments and Strategies.","volume":"16","author":"Wang","year":"2024","journal-title":"Pharmaceutics."},{"key":"B60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12929-017-0328-x","article-title":"Evaluation of the use of therapeutic peptides for cancer treatment.","volume":"24","author":"Marqus","year":"2017","journal-title":"J Biomed Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1271102","DOI":"10.3389\/fimmu.2023.1271102","article-title":"SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis.","volume":"14","author":"Pandey","year":"2023","journal-title":"Front Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/antiox9080754","article-title":"Antioxidant effects of PS5, a peptidomimetic of suppressor of cytokine signaling 1, in experimental atherosclerosis.","volume":"9","author":"La Manna","year":"2020","journal-title":"Antioxidants."},{"key":"B63","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/ijms21020378","article-title":"The novel synthetic peptide AESIS-1 exerts a preventive effect on collagen-induced arthritis mouse model via STAT3 suppression.","volume":"21","author":"Kim","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1172\/JCI25660","article-title":"SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis.","volume":"116","author":"Wong","year":"2006","journal-title":"J Clin Invest."},{"key":"B65","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1172\/JCI16156","article-title":"Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation.","volume":"111","author":"Egan","year":"2003","journal-title":"J Clin Invest."},{"key":"B66","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fmed.2020.00124","article-title":"Hi- JAKi-ng synovial fibroblasts in inflammatory arthritis with JAK inhibitors.","volume":"7","author":"Burja","year":"2020","journal-title":"Front Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s41232-023-00293-3","article-title":"Effect of JAK inhibitors on the three forms of bone damage in autoimmune arthritis: joint erosion, periarticular osteopenia, and systemic bone loss.","volume":"43","author":"Komagamine","year":"2023","journal-title":"Inflamm Regen."},{"key":"B68","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s42003-021-02944-y","article-title":"gp130\/STAT3 signaling is required for homeostatic proliferation and anabolism in postnatal growth plate and articular chondrocytes.","volume":"5","author":"Liu","year":"2022","journal-title":"Commun Biol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"4601959","DOI":"10.1155\/2017\/4601959","article-title":"SOCS1 regulates apoptosis and inflammation by inhibiting IL-4 signaling in IL-1 \u03b2-stimulated human osteoarthritic chondrocytes.","volume":"2017","author":"He","year":"2017","journal-title":"Biomed Res Int."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1002\/art.34529","article-title":"Enhanced suppressor of cytokine signaling 3 in arthritic cartilage dysregulates human chondrocyte function.","volume":"64","author":"van de Loo","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B71","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/ph15030270","article-title":"The use of Janus kinase inhibitors in axial spondyloarthritis: current Insights.","volume":"15","author":"Toussirot","year":"2022","journal-title":"Pharmaceuticals."},{"key":"B72","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/jbmr.4484","article-title":"STAT3 hyperactivation due to SOCS3 deletion in murine osteocytes accentuates responses to exercise- and load-induced bone formation.","volume":"37","author":"McGregor","year":"2022","journal-title":"J Bone Miner Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s13555-024-01203-2","article-title":"Biologics versus JAK inhibitors. part II: risk of infections. A narrative review.","volume":"14","author":"Mansilla-Polo","year":"2024","journal-title":"Dermatol Ther."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1084\/jem.20110428","article-title":"SOCS1 is essential for regulatory T cell functions by preventing loss of Foxp3 expression as well as IFN-{gamma} and IL-17A production.","volume":"208","author":"Takahashi","year":"2011","journal-title":"J Exp Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3389\/fimmu.2014.00357","article-title":"SOCS proteins in macrophage polarization and function.","volume":"5","author":"Wilson","year":"2014","journal-title":"Front Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1494901","DOI":"10.3389\/fphar.2024.1494901","article-title":"JAK inhibitors: an evidence-based choice of the most appropriate molecule.","volume":"15","author":"Antonioli","year":"2024","journal-title":"Front Pharmacol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic.","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther."},{"key":"B78","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/imm.12173","article-title":"A critical role for suppressor of cytokine signalling 3 in promoting M1 macrophage activation and function in vitro and in vivo.","volume":"141","author":"Arnold","year":"2014","journal-title":"Immunology."},{"key":"B79","doi-asserted-by":"publisher","first-page":"86","DOI":"10.22270\/ajprd.v12i6.1481","article-title":"A review on introduction, importance and applications of peptidomimetics.","volume":"12","author":"Kunal","year":"2024","journal-title":"Asian J Pharm Res Dev."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1406886","DOI":"10.3389\/fimmu.2024.1406886","article-title":"Are peptidomimetics the compounds of choice for developing new modulators of the JAK-STAT pathway?","volume":"15","author":"Cugudda","year":"2024","journal-title":"Front Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.4049\/jimmunol.178.8.5058","article-title":"Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist.","volume":"178","author":"Waiboci","year":"2007","journal-title":"J Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.exer.2018.07.020","article-title":"A cell penetrating peptide from SOCS-1 prevents ocular damage in experimental autoimmune uveitis.","volume":"177","author":"Ahmed","year":"2018","journal-title":"Exp Eye Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1167\/tvst.10.3.25","article-title":"Corneal application of R9-SOCS1-KIR peptide alleviates endotoxin-induced uveitis.","volume":"10","author":"Ahmed","year":"2021","journal-title":"Transl Vis Sci Technol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/s41374-018-0043-6","article-title":"SOCS1-targeted therapy ameliorates renal and vascular oxidative stress in diabetes via STAT1 and PI3K inhibition.","volume":"98","author":"Lopez-Sanz","year":"2018","journal-title":"Lab Invest."},{"key":"B85","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1042\/BJ20111647","article-title":"New mimetic peptides of the kinase-inhibitory region (KIR) of SOCS1 through focused peptide libraries.","volume":"443","author":"Doti","year":"2012","journal-title":"Biochem J."},{"key":"B86","doi-asserted-by":"publisher","first-page":"113547","DOI":"10.1016\/j.ejmech.2021.113547","article-title":"Cyclic mimetics of kinase-inhibitory region of suppressors of cytokine signaling 1: progress toward novel anti-inflammatory therapeutics.","volume":"221","author":"La Manna","year":"2021","journal-title":"Eur J Med Chem."},{"key":"B87","doi-asserted-by":"publisher","first-page":"114781","DOI":"10.1016\/j.ejmech.2022.114781","article-title":"Ad-hoc modifications of cyclic mimetics of SOCS1 protein: structural and functional insights.","volume":"243","author":"La Manna","year":"2022","journal-title":"Eur J Med Chem."},{"key":"B88","doi-asserted-by":"publisher","first-page":"103670","DOI":"10.1016\/j.redox.2025.103670","article-title":"Development of SOCS1 mimetics as novel approach to harmonize inflammation, oxidative stress, and fibrogenesis in metabolic dysfunction-associated steatotic liver disease.","volume":"84","author":"Bernal","year":"2025","journal-title":"Redox Biol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1002\/ijc.31594","article-title":"Mimetics of suppressor of cytokine signaling 3: novel potential therapeutics in triple breast cancer.","volume":"143","author":"La Manna","year":"2018","journal-title":"Int J Cancer."},{"key":"B90","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1021\/acsmedchemlett.9b00664","article-title":"Chimeric peptidomimetics of SOCS 3 able to interact with JAK2 as anti-inflammatory compounds.","volume":"11","author":"La Manna","year":"2020","journal-title":"ACS Med Chem Lett."},{"key":"B91","doi-asserted-by":"publisher","first-page":"117107","DOI":"10.1016\/j.ejmech.2024.117107","article-title":"Design and functional studies of xylene-based cyclic mimetics of SOCS1 protein.","volume":"282","author":"Cugudda","year":"2025","journal-title":"Eur J Med Chem."},{"key":"B92","doi-asserted-by":"publisher","first-page":"118210","DOI":"10.1016\/j.ejmech.2025.118210","article-title":"Locally constrained xylene-based cyclic mimetics of SOCS3 protein.","volume":"301","author":"Cugudda","year":"2026","journal-title":"Eur J Med Chem."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1708293\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T06:29:54Z","timestamp":1764311394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1708293\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":92,"alternative-id":["10.3389\/fmed.2025.1708293"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1708293","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"article-number":"1708293"}}